- Record: found
- Abstract: not found
- Article: not found
INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
S Verstovsek, H. KANTARJIAN, H Kantarjian, A. Pardanani, D. Thomas, J Cortes, R Mesa, J Redman, C-M Staschen, J Fridman, K. Vaddi, A Tefferi, D Thomas
2007
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.